Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ivacaftor for Chronic Bronchitis with CFTR Dysfunction
NCT03251911Phase 4Withdrawn
- Sponsor
- University of Alabama at Birmingham
- Start
- Jan 2020
- Primary completion
- Feb 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of ivacaftor in chronic bronchitis (CB) and bronchiectasis, sponsored by University of Alabama at Birmingham. Primary endpoint: Change in lung function at 1 year. Planned start Jan 2020; status: withdrawn.
02
Drugs
ivacaftor
03
Conditions
chronic bronchitis (CB)bronchiectasis
Beyond the preview
Go deeper on NCT03251911.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03251911.